Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

By | January 7, 2022
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, today announced the first participant has been dosed in the Phase 1 study of mRNA-1189, the Company’s Epstein-Barr Virus vaccine candidate.